Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening~* Documented resistance or at least six months experience prior to screening with two or more different classes of antiretroviral agents~* Stable antiretroviral regimen for at least 30 days prior to screening: however, participants may discontinue the antiretroviral regimen after screening and remain off therapy until baseline at the discretion of the investigator~* Eligible to receive one of the fully-active ritonavir-boosted-PIs, and an allowed second agent~* Normal ECG~* Adequate renal function (estimated glomerular filtration rate according to the Cockcroft-Gault formula ≥ 60 mL/min)~* Hepatic transaminases ≤ 5 × upper limit of normal~* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin~* Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm\^3; platelets ≥ 50,000/mm\^3; hemoglobin ≥ 8.5 g/dL)~* Serum amylase \< 1.5 × the upper limit of the normal range~* Negative serum pregnancy test (females of childbearing potential only)~* Males and females of childbearing potential must agree to use highly effective contraception methods~* Age ≥ 18 years~* Life expectancy ≥ 1 year~* Ability to understand and sign a written informed consent form~Exclusion Criteria:~* New AIDS-defining condition diagnosed within the 30 days prior to screening~* Prior treatment with any HIV-1 integrase inhibitor~* Participants experiencing ascites~* Participants experiencing encephalopathy~* Females who are breastfeeding~* Positive serum pregnancy test at any time during the study (female of childbearing potential)~* Participants receiving ongoing therapy with any disallowed medication~* Current alcohol or substance use judged by the investigator to potentially interfere with study compliance~* Malignancy other than cutaneous Kaposi's sarcoma or basal cell carcinoma~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline~* Participation in any other clinical trial (except for the etravirine or maraviroc expanded access program), without prior approval from sponsor~* Any other clinical condition or prior therapy that would make participants unsuitable for the study~* Known hypersensitivity to study drug, metabolites or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elvitegravir (Type: EXPERIMENTAL): EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg.
- Raltegravir (Type: ACTIVE_COMPARATOR): RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).